Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $22.00 to $23.00. They now have a "buy" rating on the stock.
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH